Patients and athletes are asking about these injectable peptides regularly, and the preclinical data is worth taking seriously
The labeling still carries the full weight of warnings from both drug classes (liver risk from acetaminophen, GI/cardiovascular risk from NSAIDs)a good reminder that "OTC" doesn't mean "no risk." I'm curious what others in the regulatory space thinkis this Rx-to-OTC trend something we'll see more of globally, including in India
Major online retailers have been identified as distributors of unapproved peptides and drugs, including TB-500, often lacking necessary disclosure about prohibited status or regulatory classification
PMID 23019153 DOI 10.1002/psc.2455 Editorially curated and source-verified
[Abstract]2025 Nov 7;11(1):511
Available in 0.3 mL, 0.5 mL, and 1 mL sizes, KDL syringes match small to high-dose needs